<DOC>
	<DOCNO>NCT00562965</DOCNO>
	<brief_summary>This protocol design assess efficacy safety inotuzumab ozogamicin give rituximab compare define investigator 's choice therapy . Subjects randomize one two arm study .</brief_summary>
	<brief_title>Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator 's Choice In Follicular Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description>On January 14th 2009 , enrollment study discontinue poor enrollment unlikely study would meet estimated enrollment approximately 978 subject . The decision prompt identification safety signal study . Active treatment follow-up already enrolled subject continue . On July , 22th 2010 , study amend shorten long-term follow-up one year active treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects diagnosis CD20 CD22positive , follicular lymphoma , receive 1 2 prior regimen , least 1 contained administration rituximab ( either single agent combination ) . Age 18 year old . ECOG performance status &lt; = 2 . ANC &gt; = 1.5 x 10^9/L ( 1500/mL ) platelet &gt; = 75 x 10^9/L ( 75,000/mL ) , serum creatinine &lt; = 1.5 x ULN urine protein creatinine ratio &lt; = 0.5 , total bilirubin &lt; = 1.5 x ULN , AST ALT &lt; = 2.5 x ULN . At least 1 measurable disease lesion &gt; = 1.5 cm x 1.5 cm CT MRI , area prior radiation therapy , document progression area previously irradiate . Subjects clinical evidence transformation aggressive subtype lymphoma grade 3b follicular lymphoma . Subjects whose disease rituximab refractory , mean CR PR , experience disease progression within 6 month initiation rituximab rituximab contain treatment regimen administer immediately precede study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>